In early June, the Hungarian National Association of Drugmakers (Magyosz) elected István Hodász as its general chairman. Hodász is CEO and managing director of the Egis Pharmaceuticals Plc, a unit of France’s Servier.
When Sanofi sells its animal health division Merial, CEO Carsten Hellmann will join Danish allergy specialist ALK Albello as the next President and CEO. He will also give up his seat on the Executive Committee and his position of Executive Vice President at Sanofi.
British research service provider Envigo has appointed Scott Schulz to the post of Director, North American Operations. Schulz joins Envigo from Taconic Biosciences, where he was VP of Operations.
Frode Marc Bohan has been reelected as Chairman of the Board of Directors for Norwegian Vitamin K2 expert NattoPharma ASA. He will continue to chair the board for the next two years.
Swedish preeclampsia drug developer A1M Pharma has named Hungarian kidney specialist József Balla as the newest member of its scientific advisory board.
Hansa Medical, a Swedish biopharmaceutical company focusing on novel immunomodulatory enzymes, has appointed Henk Doude van Troostwijk as Vice President, Commercial Operations.
Belgian CRO and service provider Genea has appointed a new Chief Medical Officer. Jörn Balzer will be responsible for the clinical, safety and risk management in Genae’s research services.
Diabetes vaccine developer Diamyd Medical has a new CEO. From now on, Ulf Hannelius will lead the Stockholm-based company.